MedTrace Logo

Pilot Trial of the First Conversational Agent for Smoking Cessation (QuitBot)

NCT03585231 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 404

Last updated 2020-12-08

No results posted yet for this study

Summary

Conversational agents (CAs) are computer-powered digital coaches designed to form long-term social-emotional connections with users through conversations. We have developed a CA for cigarette smoking cessation. In a pilot randomized trial (N = 415), we will compare the experimental messaging program (n = 155) with the standard of care national government smoking cessation messaging program (n = 157), and then we will compare immediate (n=51) versus delayed (n=51) access to the the experimental messaging program, to assess 12-week usability, receptivity, and preliminary cessation results in adults in western Washington State and nationally across the US who want to quit smoking.

Conditions

  • Smoking Cessation

Interventions

BEHAVIORAL

Immediate access to novel messaging program intervention

The experimental arm includes an immediate intervention using a novel messaging program for smoking cessation.

BEHAVIORAL

Immediate access to standard of care messaging program intervention

The immediate control intervention uses a standard of care messaging program for smoking cessation.

BEHAVIORAL

Delayed access to novel novel messaging program intervention

The delayed control intervention uses the novel messaging program for smoking cessation.

Sponsors & Collaborators

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Jonathan Bricker, PhD · Fred Hutchinson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-17
Primary Completion
2019-12-06
Completion
2020-12-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03585231 on ClinicalTrials.gov